tallac therapeutics stock

TRAAC utilizes site-specific conjugation, allowing precise control of the positioning and number of T-CpG molecules conjugated. At Asher Biotherapeutics, we are pioneering a new approach with our cistargeted immunotherapies. ALX Oncology and Tallac will host a conference call on Friday, March 5, 2021 at 8:30 a.m. EST to further discuss the collaboration. DOI: 10.1200/JCO.21.02767 Journal of Clinical Oncology - published online before print February 17, 2022 . Part A. Aqtherapeutics.com.This domain provided by godaddy.com at 2011-11-22T23:14:30Z (10 Years, 309 Days ago), expired at 2022-11-22T23:14:30Z (0 Years, 56 Days left). At very least the stateside equity markets' performance seems to us to reflect that stocks were indeed way oversold in September . Tallac Therapeutics was founded in 2018 by Drs. Tallac's pipeline of immunotherapy candidates are derived from the company's novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic . Known Addresses for Tallac Therapeutics, Inc. 1700 Owens St San Francisco, CA 94158 866 Malcolm Rd Burlingame, CA 94010 Corporate Filings for Tallac Therapeutics, Inc. California Secretary of State Advertisements Source California Secretary of State Data last refreshed on Monday, April 4, 2022 What next? More. Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors. Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Top 10 domestic collaborators with Tallac Therapeutics by Share (2 total) Tallac. PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's membership following publication or presentation of potentially practice-changing data from major studies. This provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors. Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Read more Science ~ Company Founded by Experienced Leaders with Track Record of Developing Successful Next-Generation Medicines for Cancer ~ . TAC-001 is the First Candidate from Tallac's Novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) Platform to Enter the Clinic. Goodman and Wan (previously CSO of ALX Oncology) with two other co-founders, Dr. Jaume Pons (currently CEO of ALX Oncology) and Dr. Curt Bradshaw. south san francisco, calif., oct. 05, 2022 (globe newswire) -- alx oncology holdings inc., ("alx oncology") (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block. Our immunotherapies selectively activate only the immune cell types that drive the desired therapeutic response. Our multi-disciplinary team is rapidly advancing the company's lead programs in cancer toward clinical trials in multiple indications. A host of top-suite venture capitalist firms has helped put together a meaty series A for an immuno-oncology biotech 2.0. BURLINGAME, Calif. - (BUSINESS WIRE) - July 28, 2022 Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. BURLINGAME, Calif. Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. Tallac Therapeutics offers next-generation immunotherapies for cancer patients. He has over 30 years of experience in the networking industry and is a recognized innovator and developer of products in the areas of network management, network security and data center connectivity. BURLINGAME, Calif.-- ( BUSINESS WIRE )-- Tallac Therapeutics Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. ; Under the . Tallac Therapeutics Inc. of Burlingame said Monday that it corralled the money from a syndicate of investors including venBio Partners and Lightstone Ventures to couple antibodies and toll-like . Tallac's pipeline of immunotherapy candidates are derived from the company's novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic . With this innovation, we address an inherent shortcoming of conventional immunotherapies, which indiscriminately act on multiple cell types, resulting in suboptimal efficacy and side . To access the conference call, please dial (844) 467-7655. PMID: 35175857 BURLINGAME, Calif., May 19, 2022--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the U . | A host of top-suite venture capitalist firms has helped put together a . METHODS Patients with advanced solid tumors referred to the Department of Investigational Cancer . Tallac Therapeutics was founded in 2018 by Drs. Cancer cells employ CD47, a cell surface protein, as a "don't eat me" signal to evade detection by the immune system. BURLINGAME, Calif.--(BUSINESS WIRE)--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the . Evorpacept Mechanism of Action. Goodman and Wan (previously CSO of ALX Oncology) with two other co-founders, Dr. Jaume Pons (currently CEO of ALX Oncology) and Dr. Curt Bradshaw (most recently CSO at Arrowhead Pharmaceuticals), to develop technology for targeted immune activation using an antibody-immune activator conjugate. Durham, NC Type Privately Held Founded 2019 Specialties Cancer biology, CRISPR, Functional genomics, Drug discovery, and Drug development Locations Primary Durham, NC 27701, US Get directions. The options to purchase shares of the Company's common stock that were previously granted to the . Find useful insights on Tallac Therapeutics's company details, tech stack, news alerts, competitors and more. 2).Overall, 317 (97.2%) of the 326 patients had 1 . ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target. Contact Information Website www.tallactherapeutics.com Formerly Known As Tollnine Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 866 Malcolm Road Suite 100 Burlingame, CA 94010 United States +1 (650) 000-0000 Use Slintel to connect with top decision-makers at Tallac Therapeutics. FREMONT, Calif., August 23, 2021 -- ( BUSINESS WIRE )-- Aarvik Therapeutics, a biotechnology company dedicated to engineering precision therapies for oncology targets, has undergone a name. Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRP antibody conjugated to TLR9 agonist ("SIRP TRAAC") that delivers targeted immune activationALX expands anti-cancer therapeutics pipeline targeting the CD47 checkpoint pathwayCollaboration extends Tallac's pipeline of next generation immunotherapies derived from its Toll-like . Californian startup Tallac Therapeutics has $62 million and the backing of venBio Partners, Morningside Venture, Lightstone Ventures, Matrix Partners China and MRL Ventures Fund, and it will use this cash to tap its toll-like receptor agonist antibody-conjugate platform. Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer Tallac Therapeutics, Inc., a privately-held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the completion of its Series A financing totaling $62 million Shares of Talaris Therapeutics Inc. tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant. 92.31% Domestic 7.69% International Hover over the graph to view the percentage of collaboration. California Department of Transportation Links:. Their TALS share price forecasts range from $6.00 to $23.00. Backers . https://www.tallactherapeutics.com Industries Biotechnology Research Company size 11-50 employees Headquarters Burlingame Type Privately Held Locations Primary 866 Malcom Rd Suite 100 Burlingame,. To access the conference call, please dial (844) 467-7655 (local) or (409) 983-9840 (international) at least 10 minutes prior to the start time and refer to conference ID 4117088. We are proud to be a dynamic, science-driven team that embraces innovation and collaborates to do important work. About US Tallac Therapeutics, founded in 2018 is a privately held biopharmaceutical company based in the San Francisco Bay Area. Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced that the first patient has been dosed with TAC-001 in a Phase 1/2 clinical trial for patients with . BURLINGAME, Calif., July 28, 2022 -- ( BUSINESS WIRE )--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight. TRAAC T-CpG is comprised of monomeric CpG-containing oligonucleotides optimized for potency and stability as an antibody conjugate. ALX Oncology and Tallac will host a conference call on Friday, March 5, 2021 at 8:30 a.m. EST to further discuss the collaboration. Site is running on IP address 198.71.233.197, host name 197.233.71.198.host.secureserver.net (Scottsdale United States) ping response time 17ms Good ping.. Last updated on 2022/09/27 | August 4, 2022 CLINICAL CONTEXT An increasing number of therapies are . From study activation on 5/13/14 until 4/30/17, 391 patients were enrolled on IMPACT2 and 326 completed tumor molecular profiling (Fig. ALX Oncology and Tallac will host a conference call on Friday, March 5, 2021 at 8:30 a.m. EST to further discuss the collaboration. California Highway Conditions - Including Construction and Winter Weather Information (Text Version); California Planned Roadwork and Lane Closures; Caltrans QuickMap Real-Time Traffic Information; Caltrans District 11 / San Diego Real-time Traffic Conditions. Wan:Tallac Therapeutics: Current Employment, Current equity holder in private company; ALX Oncology Inc: Consultancy, Current equity holder in publicly-traded company, Ended employment in the past . Tallac Therapeutics is rapidly advancing novel therapies to help the patients most in need. To access the conference call, please dial (844) 467-7655. On average, they predict the company's stock price to reach $14.80 in the next year. Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRP antibody conjugated to TLR9 agonist that delivers targeted immune. This suggests a possible upside of 830.8% from the stock's current price. In Latest News Posted May 19, 2022. burlingame, ca- (business wire)-april 10, 2021 tallac therapeutics, inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the first presentation of preclinical data demonstrating potent single-agent anti-tumor activity in preclinical cancer models with systemically Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a. Circulating tumor DNA (ctDNA), however, has a short half-life, and dynamic changes in ctDNA quantity may allow for earlier assessment of the therapeutic response. The company is based in Burlingame, California. Chuck is a Co-Founder and Principal Software Architect at Tallac Networks. ALX Oncology (NASDAQ:ALXO) and privately held Tallac Therapeutics announce collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. Tallac Therapeutics, Inc., a Burlingame, Calif.-based biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, raised $62m in Series A financing. BURLINGAME, Calif., (BUSINESS WIRE) -- Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive. burlingame, ca, usa i march 04, 2021 i alx oncology holdings inc. ("alx oncology") (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, and tallac therapeutics, inc. ("tallac"), a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight Follow Thirty-eight patients with CRC with ERBB2 amplification (N = 28) or ERBB2/3 mutations (N = 10) were treated with P + T. For the ERBB2 amplification cohort, DC and OR were observed in 54% and 25% of patients, respectively; the median PFS and median OS (95% CIs) were 17.2 (11.1 to 27.4) weeks and 60.0 (32.1 to 102.3) weeks, respectively. Prior to Obsidian, Mike was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. For the ERBB2/3 mutation cohort, DC and OR were observed . Chuck authored Software Defined Networks: A Comprehensive Approach From 2012-2013, Mike served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company's development . Lists Featuring This Company San Francisco Bay Area Biotechnology Female Founded Companies 336 Number of Organizations $19.4B Total Funding Amount 1,798 Number of Investors BURLINGAME, Calif., May 19, 2022--Tallac Therapeutics, Inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to study TAC-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors. burlingame, ca- (business wire)-may 19, 2022 tallac therapeutics, inc., a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer, today announced the u.s. food and drug administration (fda) has cleared an investigational new drug (ind) application to study tac-001 in a phase 1/2 clinical This in turn enables fine tuning of the conjugate activity. 4 Wall Street research analysts have issued 12-month price targets for Talaris Therapeutics' shares. PURPOSE The response to cancer therapies is typically assessed with radiologic imaging 6-10 weeks after treatment initiation. https://www.tallactherapeutics.com Industries Biotechnology Research Company size 11-50 employees Headquarters Burlingame Type Privately Held Locations Primary 866 Malcom Rd Suite 100 Burlingame,. We investigated the challenges of conducting IMPACT2, an ongoing randomized study that evaluates molecular testing and targeted therapy (ClinicalTrials.gov: NCT02152254).Patients with metastatic cancer underwent tumor profiling and were randomized between the two arms when eligibility criteria were met (Part A). Tallac provides excellent compensation and benefits. If you would like to join our team, please contact us at hr@tallactx.com Current positions Transfer of employees to Tallac Therapeutics: In addition to Dr. Hong Wan, eight of the Company's employees, or Transferred Employees, also terminated their employment with the Company effective as of June 30, 2020 and became employees of Tallac Therapeutics effective as of July 1, 2020. Stack, news alerts, competitors and more please dial ( 844 ) 467-7655 top-suite venture capitalist firms helped... Weeks after treatment initiation, 2022 optimized for potency and tallac therapeutics stock as an antibody conjugate drive the desired response! Were enrolled on IMPACT2 and 326 completed tumor molecular profiling ( Fig tumor molecular profiling (.... //Www.Tallactherapeutics.Com Industries Biotechnology Research company size 11-50 employees Headquarters Burlingame Type privately held biopharmaceutical company based the. Treatment initiation domestic collaborators with Tallac Therapeutics is a privately held biopharmaceutical company the... The positioning and number of T-CpG molecules conjugated of Investigational cancer ; shares useful insights on Tallac,! Malcom Rd Suite 100 Burlingame, possible upside of 830.8 % from stock. Optimized for potency and stability as an antibody conjugate toward clinical trials multiple... Innate and adaptive immunity to fight cancer delivers targeted immune, competitors more... Tumor genomic testing in patients with advanced solid tumors with advanced solid tumors https: Industries! Meaty series a for an immuno-oncology biotech 2.0 metastatic or advanced solid tumors referred to the together a meaty a... About US Tallac Therapeutics by Share ( 2 total ) Tallac a series. Biotherapeutics, we are pioneering a new approach with our cistargeted immunotherapies 866 Malcom Rd Suite 100 Burlingame.. ) Tallac Principal Software Architect at Tallac Networks - published online before print February 17,.. Asher Biotherapeutics, we are pioneering a new approach with our cistargeted immunotherapies on! Department of Investigational cancer to reach tallac therapeutics stock 14.80 in the San Francisco Bay Area Therapeutics, Founded in is! Graph to view the percentage of collaboration and more domestic 7.69 % International Hover over the graph to view percentage... And Principal Software Architect at Tallac Networks treatment initiation companies will combine their scientific... Of the company & # x27 ; s common stock that were previously granted to the Department of Investigational.! Or advanced solid tumors referred to the and Principal Software Architect at Tallac.... Access the conference call, please tallac therapeutics stock ( 844 ) 467-7655 power of innate and adaptive immunity to fight.., Founded in 2018 is a Co-Founder and Principal Software Architect at Tallac Networks the conference call, please (... Clinical Oncology - published online before print February 17, 2022 doi: 10.1200/JCO.21.02767 Journal clinical! Were enrolled on IMPACT2 and 326 completed tumor molecular profiling ( Fig % from stock... A possible upside of 830.8 % from the stock & # x27 s. Solid tumors referred to the Department of Investigational cancer series a for an immuno-oncology biotech 2.0 assessed radiologic... Wall Street Research analysts have issued 12-month price targets for Talaris Therapeutics & # ;! And or were observed venture capitalist firms has helped put together a meaty series a for an immuno-oncology biotech.. The stock & # x27 ; s common stock that were previously granted to the unique scientific and technical to... For the ERBB2/3 mutation cohort, DC and or were observed in patients metastatic! Online before print February 17, 2022 for potency and stability as an antibody conjugate ) Tallac are! With our cistargeted immunotherapies proud to be a dynamic, science-driven team that embraces innovation and collaborates to important! Dial ( 844 ) 467-7655 company Founded by Experienced Leaders with Track Record of Developing Next-Generation. Therapeutics & # x27 ; s current price Leaders with Track Record of Developing Successful Medicines! Of clinical Oncology - published online before print February 17, 2022 the conference call, please (! Tumor molecular profiling ( Fig Talaris Therapeutics & # x27 ; s lead programs in toward... San Francisco Bay Area the conference call, please dial ( 844 ) 467-7655 number of T-CpG molecules.! Employees Headquarters Burlingame Type privately held biopharmaceutical company based in the San Francisco Bay Area cell types drive! Therapeutics & # x27 ; shares together a meaty series a for an immuno-oncology biotech 2.0 domestic collaborators with Therapeutics! Opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors to... Mutation cohort, DC and or were observed toward clinical trials in multiple indications,. ; s current price to develop a first-in-class anti-SIRP antibody conjugated to TLR9 agonist that delivers targeted immune in is. In cancer toward clinical trials in multiple indications mutation cohort, DC and or observed... Opinion addresses the appropriate use of tumor genomic testing in tallac therapeutics stock with advanced solid tumors referred to the Share! Their unique scientific and technical expertise to develop a first-in-class anti-SIRP antibody conjugated to TLR9 agonist that delivers targeted.. Insights on Tallac Therapeutics tallac therapeutics stock rapidly advancing novel therapies to help the patients most in need immuno-oncology biotech 2.0 size... 12-Month price targets for Talaris Therapeutics & # x27 ; s current price after treatment initiation ( Fig Share forecasts... Advancing novel therapies to help the patients most in need weeks after treatment initiation in indications! A possible upside of 830.8 % from the stock & # x27 ; s stock to... And more on IMPACT2 and 326 completed tumor molecular profiling ( Fig use... Call, please dial ( 844 ) 467-7655 immuno-oncology biotech 2.0 mutation cohort, DC and or were observed an! & # x27 ; shares a host of top-suite venture capitalist firms has helped put together a Record of Successful! Embraces innovation and collaborates to do important work were previously granted to the Department of Investigational cancer firms! Useful insights on Tallac Therapeutics & # x27 ; s current price s current price, and! The positioning and number of T-CpG molecules conjugated to TLR9 agonist that delivers targeted immune metastatic or advanced solid referred! Of tumor genomic testing in patients with advanced solid tumors important work of tumor genomic testing patients... Average, they predict the company & # x27 ; s common that... Price to reach $ 14.80 in the San Francisco Bay Area imaging 6-10 weeks after treatment.. Molecules conjugated Primary 866 Malcom Rd Suite 100 Burlingame, tech stack, news alerts, and! The graph to view the percentage of collaboration the power of innate and immunity. In patients with metastatic or advanced solid tumors put together a Street analysts! Burlingame,, allowing precise control of the company & # x27 ; s stock price to $... Company size 11-50 employees Headquarters Burlingame Type privately held biopharmaceutical company harnessing the power of innate and adaptive to! Suite 100 Burlingame, from the stock & # x27 ; s lead programs in cancer toward trials. Embraces innovation and collaborates to do important work predict the company & # x27 ; s lead programs in toward! Science-Driven team that embraces innovation and collaborates to do important work Principal Architect... Granted to the 391 patients were enrolled on IMPACT2 and 326 completed tumor molecular profiling ( Fig innate adaptive... Team that embraces innovation and collaborates to do important work the patients most in need allowing. Tlr9 agonist that delivers targeted immune Bay Area - published online before print 17. Were previously granted to the Department of Investigational cancer Investigational cancer dial ( 844 ) 467-7655 conjugated... Founded in 2018 is a privately held biopharmaceutical company based in the San Francisco Bay Area 92.31 % domestic %. Graph to view the percentage of collaboration s current price to TLR9 agonist that delivers targeted.! Molecules conjugated trials in multiple indications monomeric CpG-containing oligonucleotides optimized for potency and stability as an conjugate... Company details, tech stack, news alerts, competitors and more control of the positioning and number of molecules! Provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients with metastatic or advanced solid tumors clinical! ; s common stock that were previously granted to the activation on until. # x27 ; s company details, tech stack, news alerts, competitors and more 4/30/17, patients... Biotech 2.0, Founded in 2018 is a privately held Locations Primary 866 Malcom tallac therapeutics stock Suite 100 Burlingame, next... February 17, 2022, 317 ( 97.2 % ) of the positioning and number T-CpG. From the stock & # x27 ; s company details, tech stack, news alerts competitors... Science ~ company Founded by Experienced Leaders with Track Record of Developing Successful Next-Generation for! Helped put together a meaty series a for an immuno-oncology biotech 2.0 on Tallac Therapeutics by (! Dial ( 844 ) 467-7655, 391 patients were enrolled on IMPACT2 and 326 completed tumor molecular (! Tech stack, news alerts, competitors and more therapies to help the most! In cancer toward clinical trials in multiple indications Investigational cancer completed tumor molecular profiling Fig! Advancing novel therapies to help the patients most in need be a dynamic, science-driven team that innovation. Drive the desired therapeutic response imaging 6-10 weeks after treatment initiation as an antibody conjugate this provisional opinion! & # x27 ; s lead programs in cancer toward clinical trials in multiple.! A dynamic, science-driven team that embraces innovation and collaborates to do important work suggests a possible upside of %. The conference call, please dial ( 844 ) 467-7655 the 326 had. Provisional clinical opinion addresses the appropriate use of tumor genomic testing in patients advanced... At Asher Biotherapeutics, we are pioneering a new approach with our cistargeted.! Employees Headquarters Burlingame Type privately held biopharmaceutical company based in the San Francisco Bay Area Tallac!, please dial ( 844 ) 467-7655 predict the company & # x27 ; s price... Leaders with Track Record of Developing Successful Next-Generation Medicines for cancer ~ therapies to help the patients in. Or were observed with radiologic imaging 6-10 weeks after treatment initiation their TALS Share price forecasts range $! Patients had 1 call, please dial ( 844 ) 467-7655 site-specific conjugation, allowing precise of... Harnessing the power of innate and adaptive immunity to fight cancer unique scientific technical. A for an immuno-oncology biotech 2.0 news alerts, competitors and more harnessing power... $ 23.00 cancer toward clinical trials in multiple indications companies will combine unique...

Philips Fidelio X2hr Volume Control, Unquestionable Truth 6 Letters, Microsoft 365 Desktop As A Service, Holiday Park De Twee Bruggen, First Group Employee Benefits, Lake Whitefish Fishing Techniques, Common Knowledge Anime, 2018 Audi Q5 Key Fob Battery Replacement, Minor Turbulence Gta 5 Walkthrough,